[1] |
LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin.
Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
|
[2] |
WANG Jingang, LI Qiang, SUN Huiyan, WANG Hongquan.
Recent progress in understanding the neuroprotective mechanism of carnosic acid in Parkinson's disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1073-1080.
|
[3] |
FU Xiaoyu, KONG Deguang, LI Juanjuan.
Treatment progress of triple positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
|
[4] |
LI Shixu, LI Linyun, WANG Xin, LI Ke, BIAN Hua.
Effects of Ginkgo biloba extract on renal injury in rats with experimental renal failure through miR-145/FOXO1 axis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 728-735.
|
[5] |
LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin.
The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
|
[6] |
ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge.
Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840.
|
[7] |
XIE Jingjing, YIN Hongtao, LIU Jinjin, SUN Weiming, ZHEN Donghu.
Baseline serum 25-hydroxyvitamin D3 levels and risk of metabolic syndrome: a prospective cohort study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 641-652.
|
[8] |
XU Wei, CHEN Feng, YE Zhijun.
Effectss of hyperoside on traumatic brain injury rats by regulating RhoA/ROCK signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 383-390.
|
[9] |
ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen .
Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
|
[10] |
CAO Fang, QIN Kairong, ZHENG Guoshuang, ZHAO Dewei.
Exploring the intervention mechanism of Ginkgo biloba for steroid-induced necrosis of the femoral head based on network pharmacology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 266-275.
|
[11] |
LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong.
Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282.
|
[12] |
SHEN Jiaqing, LIU Yi.
Mechanism of tyrosine kinase 2 inhibitors in treatment of plaque psoriasis and their progress in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 323-330.
|
[13] |
ZHANG Li, LIN Xingyao, SHANG Yun, WANG Qiang.
Progress on the pathological mechanism and treatment of frostbite
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 347-354.
|
[14] |
LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi .
PDE4 inhibitors serve as therapeutic targets for pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 355-360.
|
[15] |
MA Yue, MA Wangbo, ZHOU Zhihua, CHANG Jingwen, FAN Fangtian.
Intervention of quercetin in glycolysis of renal interstitial fibroblasts against interstitial fibrosis mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 121-129.
|